Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long NVO ETF

17.59
+2.8919.66%
Post-market: 19.191.60+9.10%19:59 EST
Volume:1.02M
Turnover:17.13M
Market Cap:50.98M
PE:- -
High:17.61
Open:16.70
Low:16.36
Close:14.70
52wk High:105.60
52wk Low:14.59
Shares:2.90M
Float Shares:2.80M
Volume Ratio:0.62
T/O Rate:36.36%
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Hims & Hers to Stop Offering Wegovy Copycat Drug After Regulatory Scrutiny -- Barrons.com

Dow Jones
·
2 hours ago

The Weight-Loss Price Wars Are Breaking Big Pharma's Business Model -- Heard on the Street -- WSJ

Dow Jones
·
Yesterday

Review -- Barron's

Dow Jones
·
Yesterday

Health Regulators Ask DOJ to Investigate Hims & Hers. The Stock Plunges. -- Barrons.com

Dow Jones
·
Yesterday

Health Care Up as Novo Nordisk Recoups Some Losses -- Health Care Roundup

Dow Jones
·
Yesterday

TrumpRx Is Here. Most People Won't Benefit. -- Barrons.com

Dow Jones
·
Yesterday

Hims & Hers stock nears one-year low amid battle over compounded Wegovy pill

Dow Jones
·
Yesterday

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires Live
·
Yesterday

European Markets Gain Amid Volatility as Novo Nordisk Rebound Offsets Stellantis Plunge

Deep News
·
Yesterday

Novo Nordisk A/S Stock Rises Friday, Outperforms Market

Dow Jones
·
Yesterday

Novo Nordisk’s CagriSema vs. Tirzepatide: A Key Obesity Trial Reaches Completion

TIPRANKS
·
Yesterday

Hims & Hers Shares Tumble 6.5% in Early Trading Following Legal Threats from Novo Nordisk

Deep News
·
Feb 06

These Stocks Are Today's Movers: Amazon, Strategy, Novo Nordisk, Molina, Stellantis, Impinj, Doximity, and More -- Barrons.com

Dow Jones
·
Feb 06

Update: US FDA Warns of 'Swift Action' Against Copycat Drugs

MT Newswires Live
·
Feb 06

Top Premarket Decliners

MT Newswires Live
·
Feb 06

Global Equities Roundup: Market Talk

Dow Jones
·
Feb 06

Novo Stock Jumps, Hims & Hers Tanks. This Could Shift the Weight-Loss Copycat Battle. -- Barrons.com

Dow Jones
·
Feb 06

FDA Vows Crackdown on Unapproved Weight-Loss Drug Copies, Boosting Shares of Novo Nordisk and Eli Lilly

Stock News
·
Feb 06

Goldman Sachs: Market Overpricing Novo Nordisk's Pricing Pressure, Oral Wegovy Key to Restoring Confidence

Deep News
·
Feb 06

Novo Nordisk Earnings Call: Growth Engine Meets 2026 Reset

TIPRANKS
·
Feb 06